{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:14:43Z","timestamp":1793330083171,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In-stent restenosis (ISR) is the leading cause of revascularization failure, occurring in up to 10% of patients within 10\u00a0years after drug-eluting stent (DES) implantation, and is associated with increased mortality and rehospitalization. Guideline-writing authorities recommend DES over drug-coated balloons (DCB) for ISR treatment. However, this indication is mainly based on trials that did not incorporate intravascular imaging. Recent findings suggest that optical coherence tomography (OCT) patterns in ISR may influence treatment outcomes. The ISAR-DESIRE 5 trial is a randomized study to evaluate whether OCT-defined\u00a0ISR tissue morphology affects treatment with DES versus DCB. 376 patients with ISR will be stratified by OCT pattern (homogeneous vs. non-homogeneous) and randomized 1:1 to DES or DCB. The trial is powered to detect an interaction between OCT pattern and treatment modality on the 24-month incidence of major adverse cardiac events and represents a step toward establishing a more individualized approach to ISR management.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration\u00a0(ClinicalTrials.gov):<\/jats:bold>\n                    NCT05544864.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>ISAR-DESIRE 5 Trial design overview. After classification of the predominant OCT restenotic pattern at the site of the MLA as either homogeneous or non-homogeneous, patients will undergo 1:1 randomization to receive either a DES or a DCB, using a stratified randomization approach. This unique design ensures balanced allocation of treatment modalities (DES or DCB) across the two OCT-defined restenotic patterns. DCB: Drug-Coated Balloon; DES: Drug-Eluting Stent; MLA: Minimum Lumen Area; OCT: Optical Coherence Tomography<\/jats:p>","DOI":"10.1007\/s12265-025-10650-x","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:35:41Z","timestamp":1751283341000},"page":"1176-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intracoronary Stenting and Restenosis \u2013 Randomized Trial of Drug-Eluting Stent Implantation or Drug-Coated Balloon Angioplasty According to Neointima Morphology in Drug-Eluting Stent REstenosis 5: Rationale and Design of the ISAR-DESIRE 5 Trial"],"prefix":"10.1007","volume":"18","author":[{"given":"Fiorenzo","family":"Simonetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gr\u00e4\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Janisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Manuel","family":"Leistner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Presch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rheude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Starnecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8668-4313","authenticated-orcid":false,"given":"Salvatore","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Xhepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"47","key":"10650_CR1","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","volume":"36","author":"RA Byrne","year":"2015","unstructured":"Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehv511.","journal-title":"Eur Heart J"},{"issue":"11","key":"10650_CR2","doi-asserted-by":"publisher","first-page":"e875","DOI":"10.4244\/EIJ-D-20-00487","volume":"16","author":"GG Stefanini","year":"2020","unstructured":"Stefanini GG, Alfonso F, Barbato E, Byrne RA, Capodanno D, Colleran R, et al. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EuroIntervention. 2020;16(11):e875\u201390. https:\/\/doi.org\/10.4244\/EIJ-D-20-00487.","journal-title":"EuroIntervention"},{"issue":"2","key":"10650_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/eurheartj\/ehu383","volume":"36","author":"S Cassese","year":"2015","unstructured":"Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, et al. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. Eur Heart J. 2015;36(2):94\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehu383.","journal-title":"Eur Heart J"},{"issue":"5","key":"10650_CR4","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.4244\/EIJ-D-19-01031","volume":"17","author":"H Tamez","year":"2021","unstructured":"Tamez H, Secemsky EA, Valsdottir LR, Moussa ID, Song Y, Simonton CA, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021;17(5):e380\u20137. https:\/\/doi.org\/10.4244\/EIJ-D-19-01031.","journal-title":"EuroIntervention"},{"issue":"13","key":"10650_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jacc.2020.08.002","volume":"76","author":"ID Moussa","year":"2020","unstructured":"Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, et al. Trends and outcomes of restenosis after coronary stent implantation in the United States. J Am Coll Cardiol. 2020;76(13):1521\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.002.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10650_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","volume":"80","author":"G Giustino","year":"2022","unstructured":"Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(4):348\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2022.05.017.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10650_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.jacc.2020.08.035","volume":"76","author":"A Kastrati","year":"2020","unstructured":"Kastrati A, Cassese S. In-stent restenosis in the United States: time to enrich its treatment armamentarium. J Am Coll Cardiol. 2020;76(13):1532\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.035.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10650_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","volume":"8","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6): e002230. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.002230.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"10650_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12928-017-0458-9","volume":"33","author":"K Nakatsuma","year":"2018","unstructured":"Nakatsuma K, Shiomi H, Natsuaki M, Morimoto T, Igarashi K, Kadota K, et al. Second-generation versus first-generation drug-eluting stents in patients with and without diabetes mellitus: pooled analysis from the RESET and NEXT trials. Cardiovasc Interv Ther. 2018;33(2):125\u201334. https:\/\/doi.org\/10.1007\/s12928-017-0458-9.","journal-title":"Cardiovasc Interv Ther"},{"issue":"3","key":"10650_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/CIRCULATIONAHA.118.038065","volume":"139","author":"S Kufner","year":"2019","unstructured":"Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation. 2019;139(3):325\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038065.","journal-title":"Circulation"},{"issue":"8","key":"10650_CR11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jcin.2014.02.014","volume":"7","author":"LO Jensen","year":"2014","unstructured":"Jensen LO, Thayssen P, Maeng M, Christiansen EH, Ravkilde J, Hansen KN, et al. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial. JACC Cardiovasc Interv. 2014;7(8):840\u20138. https:\/\/doi.org\/10.1016\/j.jcin.2014.02.014.","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10650_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jcin.2015.03.028","volume":"8","author":"PC Smits","year":"2015","unstructured":"Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). JACC Cardiovasc Interv. 2015;8(9):1157\u201365. https:\/\/doi.org\/10.1016\/j.jcin.2015.03.028.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"10650_CR13","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.jcin.2015.04.032","volume":"8","author":"H Kawamoto","year":"2015","unstructured":"Kawamoto H, Ruparelia N, Latib A, Miyazaki T, Sato K, Mangieri A, et al. Drug-coated balloons versus second-generation drug-eluting stents for the management of recurrent multimetal-layered in-stent restenosis. JACC Cardiovasc Interv. 2015;8(12):1586\u201394. https:\/\/doi.org\/10.1016\/j.jcin.2015.04.032.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"10650_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.005935","volume":"11","author":"H Yabushita","year":"2018","unstructured":"Yabushita H, Kawamoto H, Fujino Y, Tahara S, Horikoshi T, Tada M, et al. Clinical outcomes of drug-eluting balloon for in-stent restenosis based on the number of metallic layers. Circ Cardiovasc Interv. 2018;11(8): e005935. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.117.005935.","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"10650_CR15","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.4244\/EIJ-D-21-01034","volume":"18","author":"F Alfonso","year":"2022","unstructured":"Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention. 2022;18(2):e103\u201323. https:\/\/doi.org\/10.4244\/EIJ-D-21-01034.","journal-title":"EuroIntervention"},{"issue":"15","key":"10650_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.jcin.2024.05.0385","volume":"17","author":"J Cuesta","year":"2024","unstructured":"Cuesta J, Perez-Vizcayno MJ, Garcia Del Blanco B, Bosa F, de Prado AP, Rumoroso JR, et al. Long-term results of bioresorbable vascular scaffolds in patients with in-stent restenosis: the RIBS VI study. JACC Cardiovasc Interv. 2024;17(15):1825\u201336. https:\/\/doi.org\/10.1016\/j.jcin.2024.05.0385.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"10650_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4244\/EIJ-D-17-01079","volume":"14","author":"CJ Jensen","year":"2018","unstructured":"Jensen CJ, Richardt G, Tolg R, Erglis A, Skurk C, Jung W, et al. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. EuroIntervention. 2018;14(10):1096\u2013103. https:\/\/doi.org\/10.4244\/EIJ-D-17-01079.","journal-title":"EuroIntervention"},{"issue":"9865","key":"10650_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(12)61964-3","volume":"381","author":"RA Byrne","year":"2013","unstructured":"Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(12)61964-3.","journal-title":"Lancet"},{"issue":"10","key":"10650_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jcin.2018.02.037","volume":"11","author":"F Alfonso","year":"2018","unstructured":"Alfonso F, Perez-Vizcayno MJ, Cuesta J, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. 3-year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. JACC Cardiovasc Interv. 2018;11(10):981\u201391. https:\/\/doi.org\/10.1016\/j.jcin.2018.02.037.","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"10650_CR20","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.jacc.2010.02.009","volume":"55","author":"J Mehilli","year":"2010","unstructured":"Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010;55(24):2710\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.009.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10650_CR21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.carrev.2018.08.010","volume":"20","author":"IY Elgendy","year":"2019","unstructured":"Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, et al. Drug-eluting balloons versus everolimus-eluting stents for in-stent restenosis: a meta-analysis of randomized trials. Cardiovasc Revasc Med. 2019;20(7):612\u20138. https:\/\/doi.org\/10.1016\/j.carrev.2018.08.010.","journal-title":"Cardiovasc Revasc Med"},{"issue":"24","key":"10650_CR22","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/j.jcin.2016.09.016","volume":"9","author":"C Lutter","year":"2016","unstructured":"Lutter C, Mori H, Yahagi K, Ladich E, Joner M, Kutys R, et al. Histopathological differential diagnosis of optical coherence tomographic image interpretation after stenting. JACC Cardiovasc Interv. 2016;9(24):2511\u201323. https:\/\/doi.org\/10.1016\/j.jcin.2016.09.016.","journal-title":"JACC Cardiovasc Interv"},{"issue":"42","key":"10650_CR23","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1093\/eurheartj\/eht241","volume":"34","author":"M Nakano","year":"2013","unstructured":"Nakano M, Otsuka F, Yahagi K, Sakakura K, Kutys R, Ladich ER, et al. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J. 2013;34(42):3304\u201313. https:\/\/doi.org\/10.1093\/eurheartj\/eht241.","journal-title":"Eur Heart J"},{"issue":"2","key":"10650_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ahj.2009.06.004","volume":"158","author":"N Gonzalo","year":"2009","unstructured":"Gonzalo N, Serruys PW, Okamura T, van Beusekom HM, Garcia-Garcia HM, van Soest G, et al. Optical coherence tomography patterns of stent restenosis. Am Heart J. 2009;158(2):284\u201393. https:\/\/doi.org\/10.1016\/j.ahj.2009.06.004.","journal-title":"Am Heart J"},{"issue":"10","key":"10650_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/ehjci\/jev031","volume":"16","author":"T Tada","year":"2015","unstructured":"Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, et al. Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Eur Heart J Cardiovasc Imaging. 2015;16(10):1101\u201311. https:\/\/doi.org\/10.1093\/ehjci\/jev031.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10650_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ehjci\/jet165","volume":"15","author":"T Tada","year":"2014","unstructured":"Tada T, Kadota K, Hosogi S, Miyake K, Amano H, Nakamura M, et al. Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with plain old balloon angioplasty. Eur Heart J Cardiovasc Imaging. 2014;15(3):307\u201315. https:\/\/doi.org\/10.1093\/ehjci\/jet165.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"10650_CR27","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.4244\/EIJ-D-20-00662","volume":"17","author":"E Xhepa","year":"2021","unstructured":"Xhepa E, Bresha J, Joner M, Hapfelmeier A, Rivero F, Ndrepepa G, et al. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. EuroIntervention. 2021;17(5):e388\u201395. https:\/\/doi.org\/10.4244\/EIJ-D-20-00662.","journal-title":"EuroIntervention"},{"issue":"14","key":"10650_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jcin.2018.02.029","volume":"11","author":"M Joner","year":"2018","unstructured":"Joner M, Koppara T, Byrne RA, Castellanos MI, Lewerich J, Novotny J, et al. Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (A Report of the PRESTIGE Consortium). JACC Cardiovasc Interv. 2018;11(14):1340\u201350. https:\/\/doi.org\/10.1016\/j.jcin.2018.02.029.","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10650_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00392-019-01439-5","volume":"108","author":"E Xhepa","year":"2019","unstructured":"Xhepa E, Byrne RA, Rivero F, Rroku A, Cuesta J, Ndrepepa G, et al. Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. Clin Res Cardiol. 2019;108(9):1059\u201368. https:\/\/doi.org\/10.1007\/s00392-019-01439-5.","journal-title":"Clin Res Cardiol"},{"issue":"32","key":"10650_CR30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","volume":"36","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147\u201359. https:\/\/doi.org\/10.1093\/eurheartj\/ehv205.","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10650-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:11:35Z","timestamp":1763565095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10650-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10650"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10650-x","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that patient consent forms will be obtained for the enrollment in this study. This trial will be conducted in accordance with the Declaration of Helsinki, ISO 14155, and applicable local laws and regulations. The protocol, amendments, and the subject's informed consent were approved by all participating sites'independent ethics committees (IEC). No animal studies were carried out by the authors for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent and Ethics Statements"}},{"value":"Dr.Kuna received speaker fee from AstraZeneca; Dr. Voll received speaking fees from AstraZeneca, Translumina Therapeutics, SIS-Medical and Abbott educational Grants by Abbott, SIS-Medical and Inari Medical. E. Xhepa reports consulting services for Edwards Lifesciences, lecture fees and honoraria from Abbott Vascular, AstraZeneca, Boston Scientific and SIS Medical not related to the current work; proctor fees from Abbott Vascular and financial support for attending meetings and\/or travel expenses from Abbott Vascular and SIS Medical. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}